The estimated Net Worth of Deborah M. Messemer is at least $1.33 Milione dollars as of 18 June 2024. Ms. Messemer owns over 18,641 units of Allogene Therapeutics Inc stock worth over $485,286 and over the last 6 years she sold ALLO stock worth over $365,446. In addition, she makes $482,488 as Independent Director at Allogene Therapeutics Inc.
Sign up
Ms. Messemer ALLO stock SEC Form 4 insiders trading
Deborah has made over 3 trades of the Allogene Therapeutics Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently she sold 18,641 units of ALLO stock worth $42,501 on 18 June 2024.
The largest trade she's ever made was selling 18,641 units of Allogene Therapeutics Inc stock on 18 June 2024 worth over $42,501. On average, Deborah trades about 2,606 units every 11 days since 2018. As of 18 June 2024 she still owns at least 166,765 units of Allogene Therapeutics Inc stock.
You can see the complete history of Ms. Messemer stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Deborah Messemer biography
Deborah M. Messemer serves as Independent Director of the Company. Ms. Messemer currently serves as director of PayPal Holdings, Inc. (since January 2019) and of Carbon, Inc. (since November 2018). Ms. Messemer is a certified public accountant and joined KPMG LLP (KPMG), the U.S. member firm of KPMG International, in 1982 and was admitted into the partnership in 1995. Most recently, she served as the Managing Partner of KPMG’s Bay Area and Northwest region until her retirement in September 2018. Ms. Messemer spent the majority of her career in KPMG’s audit practice as an audit engagement partner serving public and private clients in a variety of industry sectors. In addition to her operational and audit signing responsibilities, she has significant experience in SEC filings, due diligence, initial public offerings, mergers and acquisitions, and internal controls over financial reporting. Ms. Messemer is a member of the National Association of Corporate Directors and co-founder of the San Francisco Chapter of Women Corporate Directors. She has served on a number of non-profit and advisory boards including the Bay Area Council, the San Francisco Committee on Jobs, the California Chamber of Commerce, the San Francisco Chamber of Commerce, the UC Berkeley Fisher Center Policy Advisory Board, San Francisco Ballet, and Posse. Ms. Messemer received a bachelor’s degree in accounting from the University of Texas at Arlington.
What is the salary of Deborah Messemer?
As the Independent Director of Allogene Therapeutics Inc, the total compensation of Deborah Messemer at Allogene Therapeutics Inc is $482,488. There are 15 executives at Allogene Therapeutics Inc getting paid more, with David Chang having the highest compensation of $11,192,100.
Insiders trading at Allogene Therapeutics Inc
Over the last 6 years, insiders at Allogene Therapeutics Inc have traded over $137,494,387 worth of Allogene Therapeutics Inc stock and bought 2,891,304 units worth $29,333,135 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Arie Belldegrun e Inc Pfizer. On average, Allogene Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $286,894. The most recent stock trade was executed by Deborah M. Messemer on 18 June 2024, trading 18,641 units of ALLO stock currently worth $42,501.
What does Allogene Therapeutics Inc do?
allogene therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor t-cell (car t) therapy directed at blood cancers and solid tumors. founded and led by former kite pharma executives who bring unrivaled clinical development acumen in cell therapy, allogene is well-positioned to further the potential of allogeneic cell therapy for patients. allogeneic car t therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. this approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for car t treatment. the allogene portfolio includes 16 pre-clinical t cell therapy assets and ucart19, an allogeneic car t therapy currently in phase 1 development for the treatment of acute lymphoblastic leukemia (all). through its notable partnerships, allogene le
What does Allogene Therapeutics Inc's logo look like?
Complete history of Ms. Messemer stock trades at PayPal Inc e Allogene Therapeutics Inc
Allogene Therapeutics Inc executives and stock owners
Allogene Therapeutics Inc executives and other stock owners filed with the SEC include:
-
David Chang,
President, Chief Executive Officer, Co-Founder, Director -
Rafael Amado,
Executive Vice President - Research and Development, Chief Medical Officer -
Arie Belldegrun,
Executive Chairman of the Board -
Eric Schmidt,
Chief Financial Officer -
Alison Moore,
Chief Technical Officer -
Dr. David D. Chang M.D., Ph.D.,
Co-Founder, Pres, CEO & Director -
Joshua Kazam,
Co-Founder, Director -
Dr. Rafael G. Amado M.D.,
Exec. VP of R&D -
Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D.,
Co-Founder & Exec. Chairman -
Dr. Arie S. Belldegrun F.A.C.S., M.D., FACS,
Co-Founder & Exec. Chairman -
Dr. Rafael G. Amado,
Chief Medical Officer and Exec. VP of R&D -
Dr. Alison Moore Ph.D.,
Chief Technical Officer -
Dr. Eric Thomas Schmidt Ph.D.,
Chief Financial Officer -
Veer Bhavnagri,
Gen. Counsel & Compliance Officer -
Franz Humer,
Independent Director -
Deborah Messemer,
Independent Director -
Owen Witte,
Independent Director -
Joshua A. Kazam,
Co-Founder & Director -
Veer Bhavnagri,
Chief Compliance Officer, General Counsel -
Todd Sisitsky,
Independent Director -
John DeYoung,
Independent Director -
David Bonderman,
Lead Independent Director -
Stephen Cheng,
Chief Information Officer -
David M. Tanen J.D.,
Sec. -
Christine Cassiano,
Chief Communications Officer -
Barbra Sasu,
Chief Scientific Officer -
Timothy L. Moore,
Chief Technical Officer -
Yinlin Jack Chen,
SVP, Finance -
Inc Pfizer,
10% owner -
Earl Martin Douglas,
SVP, General Counsel -
Elizabeth A. Barrett,
-
Vicki L Sato,
-
Equity Holdings 2 B.V. Pf,
10% owner -
Stephen Mayo,
-
Zachary Roberts,
EVP of R&D -
Lillian Smith,
VP, Corporate Counsel -
Geoffrey M. Parker,
CHIEF FINANCIAL OFFICER